KUALA LUMPUR: A new affordable hepatitis C treatment will soon be introduced in Malaysia, making it possible for patients to receive treatment for the potentially fatal disease.
Malaysian pharmaceutical company Pharmaniaga
Logistics Sdn Bhd, Egyptian pharmaceutical company Pharco Pharmaceuticals (Pharco) and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration agreement to supply a new hepatitis C treatment regimen to be sold for US$300 ((RM1,257) in the public sector in Malaysia.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
